Figure 1A
Five patients died in the RDAVR group, exclusively from non-cardiovascular causes. In the TAVR group, 13 patients died, mainly from a cardiovascular causes including CHF (n=6), myocardial infarction (n=1), sudden cardiac death (n=1) and infective endocarditis (n=1). By propensity score matching analysis, there was a trend in favor of RDAVR concerning all-cause mortality without reaching statistical significance (HR = 0.40[95%CI:0.12,1.14], p=0.08). Figure 1B
Five patients were hospitalized in the RDAVR group, exclusively due to congestive heart failure (CHF). In the TAVR, 10 patients were hospitalized, mainly due to CHF (80%). The rate of re-hospitalization related to the procedure, the valve, or heart failure at two-years FU was 39.58% in the RDAVR group and 60.42% in the TAVR group. By propensity score matching analysis, there was a significant difference between both groups in favor of RDAVR (HR=0.56[95%CI 0.32,1.0], p=0.04). Figure 1C
No disabling stroke occurred in the RDAVR group and one (2.08%) occurred in TAVR group.